Advertisement
Screener

Royalty Pharma plc (RPRX) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Royalty Pharma plc Cash Flow Breakdown

Cash flow breakdown shows where Royalty Pharma plc's cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $2.49B came in.
  • Fiscal year ended 2025-12-31: from investing, $1.61B went out.
  • Fiscal year ended 2025-12-31: from financing, $1.19B went out.
  • Fiscal year ended 2025-12-31: change in cash, $310.33M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingBuybacksDebt paid backNew debtCommercial paperOtherNot split outChange in cash
2025-12-31$2.49B-$1.61B-$1.23B-$1.27B-$1.79M$1.32B*-$310.33M
2024-12-31$2.77B-$2.68B-$229.65M$0.00-$9.03M$599.82M*$452.02M
2023-12-31$2.99B-$2.07B-$304.76M-$350.00M$0.00-$1.49B*-$1.23B
2022-12-31$2.14B-$1.03B$0.00$0.00$0.00$0.00-$944.86M*$169.70M
2021-12-31$2.02B-$1.87B$0.00$385.11M*$532.37M
2020-12-31$2.03B-$2.76B$0.00-$11.12B$11.89B$712.34M*$762.48M
2019-12-31$1.67B-$2.15B-$4.27M$0.00$0.00-$1.19B*-$1.68B
2018-12-31$1.62B$303.42M$0.00$0.00$0.00-$1.38B*$542.64M

Each quarter (3 month)

Quarter endRunning the businessFrom investingBuybacksDebt paid backNew debtCommercial paperOtherNot split outChange in cash
2026-06-30$728.46M*-$229.72M*-$44.64M*-$389.00K*-$228.12M*
2026-03-31$718.23M-$477.87M-$50.10M-$226.00K-$222.34M*-$32.30M
2025-12-31$827.15M*-$847.80M*-$80.54M*$0.00*-$1.79M*-$217.27M*
2025-09-30$702.62M*-$958.31M*-$146.49M*$0.00*$709.23M*
2025-06-30$363.98M*-$311.98M*-$291.57M*$0.00*-$216.24M*
2025-03-31$596.08M$503.92M-$708.78M$0.00-$232.52M*$158.69M
2024-12-31$742.52M*-$505.59M*-$52.61M*$0.00*-$1.00K*-$205.35M*
2024-09-30$703.61M*-$1.19B*-$97.05M*$2.00K*-$228.46M*
2024-06-30$658.21M*-$893.18M*-$80.00M*$1.24B*
2024-03-31$664.64M-$86.65M$0.00-$212.00M*$365.99M
2023-12-31$772.63M*-$1.00B*-$30.20M*$0.00*-$201.69M*
2023-09-30$573.52M*-$450.66M*-$140.12M*$0.00*-$1.22B*
2023-06-30$607.82M*-$63.43M*-$347.00M*
2023-03-31$1.03B-$558.53M-$210.37M*$264.94M
2022-12-31$569.93M*$414.74M*$0.00*$0.00*$0.00*-$265.55M*
2022-09-30$538.83M*-$1.43B*$0.00*-$230.09M*
2022-06-30$574.95M*-$30.18M*-$228.25M*
2022-03-31$460.27M$11.16M-$220.97M*$250.47M
2021-12-31$489.96M*-$551.65M*$0.00*$0.00*-$198.07M*
2021-09-30$469.76M*-$845.50M*$0.00*$1.27B*-$238.26M*
2021-06-30$531.72M*$126.17M*$0.00*$0.00*-$224.41M*
2021-03-31$526.10M-$599.30M$0.00$0.00-$226.67M*-$299.87M
2020-12-31$565.67M*-$832.40M*$0.00*$0.00*$0.00*-$277.39M*
2020-09-30$508.85M*-$920.20M*$0.00*-$5.95B*$5.85B*-$262.62M*
2020-06-30$489.00M*-$244.97M*$0.00*$0.00*$1.58B*
2020-03-31$471.10M-$761.75M-$5.17B$6.04B-$327.08M*$251.87M
2019-12-31$478.43M*-$62.82M*-$38.00K*$0.00*$0.00*-$285.76M*
2019-09-30$419.03M*-$615.27M*$0.00*$0.00*$0.00*-$280.69M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Zoetis Inc. (ZTS)United States$29.045B11.38
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80